Natco Pharma Ltd.

The U.S. Food and Drug Administration (USFDA) has granted approval to Natco Pharma’s partner Breckenridge Pharmaceutical Inc’s Abbreviated New Drug Application (ANDA) for Cabazitaxel Intravenous Powder (generic for Jevtana Kit) for the 60mg/1.5mL (40mg/mL) strength.

Breckenridge and Natco are unable to make further comment regarding the launch date for the product, as that is confidential and cannot be disclosed at this time. According to industry sales data, Jevtana Kit generated annual sales of $303 million during the twelve months ending May 2022.

Natco Pharma was promoted as a private company to be in the business of research, developing, manufacturing and marketing of pharmaceutical substances and finished dosage forms for Indian and International markets.